Data / Drug companies / Doxazosin mesylate
Doxazosin mesylate: 12 companies and 39 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Doxazosin mesylate is listed in the FDA National Drug Code Directory by 12 companies, with 39 products in commercial distribution. 32 of the products (82.1%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet; tablet, film coated, extended release, and the newest product started marketing on August 3, 2026.
The request: Get every company that lists doxazosin mesylate in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 12
- Products
- 39
- Generic (ANDA) products
- 32 (82.1%)
- Application numbers
- 7
- Routes
- Oral
- Brand names
- Doxazosin, Cardura XL
- openFDA record search
- api.fda.gov
Companies that list doxazosin mesylate
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| A-S Medication Solutions | 4 | tablet | Generic drugs (ANDA) | April 17, 2018 |
| Aurobindo Pharma Limited | 4 | tablet | Generic drugs (ANDA) | March 1, 2024 |
| Bryant Ranch Prepack | 4 | tablet | Generic drugs (ANDA) | April 17, 2018 |
| Chartwell RX, LLC | 4 | tablet | Generic drugs (ANDA) | October 18, 2000 |
| Mylan Pharmaceuticals Inc. | 4 | tablet | Authorized generics (NDA) | August 3, 2026 |
| Teva Pharmaceuticals USA, Inc. | 4 | tablet | Generic drugs (ANDA) | December 5, 2014 |
| Unichem Pharmaceuticals (USA), Inc. | 4 | tablet | Generic drugs (ANDA) | January 10, 2024 |
| Upsher-Smith Laboratories, LLC | 4 | tablet | Generic drugs (ANDA) | April 17, 2018 |
| Aphena Pharma Solutions - Tennessee, LLC | 3 | tablet | Generic drugs (ANDA) | September 24, 2025 |
| Viatris Specialty LLC | 2 | tablet, film coated, extended release | New drug applications (NDA) | April 23, 2024 |
| Northwind Health Company, LLC | 1 | tablet | Generic drugs (ANDA) | February 27, 2023 |
| Unichem Laboratories Limited, India | 1 | tablet | Generic drugs (ANDA) | January 10, 2024 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 37 | 94.9% |
| Tablet, film coated, extended release | 2 | 5.1% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 32 | 82.1% |
| Authorized generics (NDA) | 5 | 12.8% |
| New drug applications (NDA) | 2 | 5.1% |
Pharmacologic classes
| Class | Products |
|---|---|
| alpha-Adrenergic Blocker | 39 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.